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Assuring the Patient Centeredness of Patient-Reported Outcomes:
Content Validity in Medical Product Development and Comparative
Effectiveness ResearchNot all patient-reported outcomes (PROs) are patient centered, and
not all patient-centered outcomes are patient reported.
The essential characteristic of a patient-centered approach to
outcome measurement is that it assesses concepts (i.e., health-
related phenomena) that are considered most important by mem-
bers of a given target population, based on direct input from rep-
resentatives of that population. Concepts for measurement
should not be selected based solely on convenience or interest to
investigators. Patient-centered patient-reported outcome measures
ust meet this criterion and also be meaningful and comprehen-
ible to members of a population when administered, including
mong those with diverse racial/cultural backgrounds and lower
ducational/literacy levels.
An example of a PRO measure that is not optimally patient
entered is the Present Pain Intensity item of the McGill Pain Ques-
ionnaire [1]. The Present Pain Intensity item has been used as a
RO measure in multiple phase III clinical trials in the regulatory
ontext (including serving as the basis for U.S. drug approval and
abeling of the cancer drug mitoxantrone in 1996) [2]. This mea-
ure, however, was initially developed for clinician reporting and
ever underwent qualitative evaluation with direct patient input.
he item asks respondents:
How strong is your pain?
1 2 3 4 5
Mild Discomforting Distressing Horrible Excruciating
The response options mix up the attributes of intensity (“mild”)
and bother (“distressing”), and the distinctions between options at
each extreme of the scale are not clear (“mild” vs. “discomforting”
and “horrible” vs. “excruciating”). Item development with direct
patient input, and cognitive interviewing to ensure patient under-
standing, would likely have yielded different response options.
These limitations were highlighted at a meeting of the Food and
Drug Administration’s (FDA’s) Oncology Drug Advisory Commit-
tee in 2007 [3], just subsequent to the issuance of FDA’s 2006 draft
uidance for industry: Patient-reported outcomes measures: Use in med-
cal product development to support labeling claims (issued in final
form in 2009) [4]. Subsequently, use of the “worst pain item” of the
rief Pain Inventory has been advocated by the FDA for pain in-
ensity assessment in the regulatory context [5].
Because the Present Pain Intensity item was not developed
with a patient-centered approach, its ability to adequately assess
the patient pain experience associated with disease and treatment
is in question. Viewing this same concept through a patient lens, a
patient-centered PRO measure must be understandable to pa-tients with a variety of backgrounds, which requires direct patient
input during development and revisions.
In contrast, a measure can be patient centered without being a
PRO. For example, exercise capacity is an important concept to
patients in selected contexts and is best evaluated with an objec-
tive approach such as a treadmill test.
These examples highlight the importance of thoughtfulness
when selecting or developing outcomes for use in clinical re-
search. As alluded to above, this applies both to the identification of
concepts to be evaluated as outcomes in a given context and to the
development of outcome measures for assessing these concepts.
The two-part article on content validity in this issue of Value in
Health [6,7] provides an important contribution to the methodolog-
ical literature and complements FDA’s PRO Guidance toward stan-
dardizing methods for the development of end-point models and
PRO instruments that are optimally patient centered. The key
message of this article is the importance of directly eliciting the
patient perspective through qualitative research during identifi-
cation of concepts to be evaluated (whether patient reported or
not) and development/refinement of PRO measures.
There have been critiques of FDA’s PRO Guidance as setting too
high a methodological bar for sponsors to attain and of its ap-
proach to content validity as being overly focused on qualitative
over quantitative methods [8]. While there is some truth to these
assertions, the overall impact of FDA’s emphasis on qualitative
methods has been positive, leading investigators in both the reg-
ulatory and nonregulatory spaces to focus on the patient perspec-
tive, thus creating a need for a blueprint as provided by the two-
part article in this issue.
A potential limitation of the methods described in this two-
part article is reliance on the good faith and judgment of investi-
gators who are interpreting qualitative data to decide which con-
cepts are most appropriate to measure in a given context. There is
a risk that investigators will select concepts for measurement that
cast a particular product in the most positive light while ignoring
other concepts that could appear less favorable. For example, if a
product reduces pain but increases nausea, investigators could
choose to evaluate only the former although both are important to
patients.
This misuse of the regulatory tenet of “fit-for-use” end-point
design risks conveying an incomplete picture of the impact of
treatment on the patient’s subjective experience. In fact, in part
one of this article, in the discussion titled “Understand the disease
or condition in the target population” it is acknowledged that “The
selection of outcomes appropriate for a given trial program is often
informed by consultation with clinical, trial design, and measure-
ment experts as well as an extensive literature review.”
Therefore, a key item for investigators who are developing a
new PRO measure, or selecting an existing measure for use in a
[966 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 9 6 5 – 9 6 6new study, is to 1) describe all the concepts reported as important
by patients in the target population or in a closely related popula-
tion and 2) provide a rationale for which concepts were included or
excluded.
How do the recommendations of this two-part article, which
largely apply to the regulatory context (and largely to the U.S. reg-
ulatory context), apply to comparative effectiveness research
(CER)? For prospective CER controlled clinical studies, the recom-
mendations should be taken virtually intact, with a particular em-
phasis on developing conceptual frameworks for the relationships
of various outcomes—as elegantly shown for psoriasis in Figure 1
of part one of the article. But the “fit for purpose” focus of the
regulatory setting is less applicable to other CER approaches such
as registries or longitudinal observational studies that are often
more exploratory in nature. In such instances, inclusion of a
broader selection of outcomes, some intended for signal genera-
tion beyond initial qualitative work, is merited. For example, a
multi-item symptom or health-related quality-of-life battery is
appropriate, in addition to measurement of context-specific con-
cepts of interest. Regardless, upfront qualitative research to iden-
tify salient concepts prior to conducting any type of prospective
clinical CER is strongly recommended. It is critical to remember
that research to inform care of patients—and to be understood and
interpreted by patients—is one of the targets of CER; hence pa-
tient-centered PRO measures need to be consistently understand-
able and meaningful to patients themselves, and this generally
requires patient input up front. Notably, additional qualitative
evaluations with patients after completing quantitative psycho-
metric studies can also be informative. For example, in the psy-
chometric analysis of a patient-reported measure, an item re-
sponse bias could be detected (i.e., differential item functioning)
between Hispanic and non-Hispanic patients. Statistical tools can
identify differential item functioning, but it requires qualitative
work to illuminate the underlying drivers of these differences.
Qualitative methods can also be incorporated into prospective
clinical research to provide insights about patient perspectives at
key time points, or about the relationships of outcomes with each
other or with interventions. Once a measure is developed, it
should be periodically re-evaluated as treatment paradigms and
patient perspectives shift over time, to ensure that it remains ap-
propriate and representative of meaningful concepts.
As noted in the two-part article, central to the importance of
conducting qualitative evaluations for establishing content valid-
ity in the regulatory and CER environments is inclusion of a het-
erogeneous sample within the target population. In addition to
including representatives of various racial/cultural or applicable
linguistic backgrounds, those with diverse educational/literacy
levels should be included. Moreover, methodological expertise to
analyze these data and adjust verbiage accordingly is recom-
mended. Patients with higher educational levels are easier to iden-
tify and recruit in clinical research, and therefore efforts must be
made to include hard-to-reach individuals. For example, it is a
requirement in the development work of two U.S. National Insti-
tutes of Health initiatives, the Patient-Reported Outcomes Mea-
surement Information System (PROMIS) and the Patient-Reported
Outcomes version of the Common Terminology Criteria for Ad-
verse Events (PRO-CTCAE), to include cognitive interviews among
patients with low education levels (e.g., 12 years of education or
measured reading level ninth grade using the Wide Range
Achievement Test-3 Reading subtest) [9,10].
In summary, qualitative research is essential for identifying
concepts for measurement in a given target population, for refin-
ing measures that assess these concepts, and for continued assur-
ance that the concepts and measures remain appropriate and
meaningful over time. This work should include hard-to-reach
patients, particularly those of diverse racial/cultural and educa-tional/literacy levels. This approach applies both to trials in the
regulatory context and to prospective clinical CER. Beginning this
process as early as possible in a given research program will afford
an opportunity to develop or select appropriate concepts and mea-
sures that are optimally patient centered.
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